-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AeKNfg0D188n/e/RCDXlGfZWbvse4MvrCBfnHfLYwzRAqWHU20kCyrQglidvHMIP l6K5sGUnuPRhQGK1OKzgqA== 0001230295-06-000036.txt : 20060222 0001230295-06-000036.hdr.sgml : 20060222 20060222170958 ACCESSION NUMBER: 0001230295-06-000036 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060215 FILED AS OF DATE: 20060222 DATE AS OF CHANGE: 20060222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fink David L CENTRAL INDEX KEY: 0001321462 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 06636856 BUSINESS ADDRESS: BUSINESS PHONE: 732-418-9300 MAIL ADDRESS: STREET 1: C/O SAVIENT PHARMACEUTICALS, INC. STREET 2: ONE TOWER CENTER BLVD., 14TH FL. CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 4 1 fin41.xml X0202 4 2006-02-15 0 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001321462 Fink David L C/O SAVIENT PHARMACEUTICALS, INC. ONE TOWER CENTER BLVD., 14TH FLOOR EAST BRUNSWICK NJ 08816 0 1 0 0 SVP, Commercial Operations Common Stock, $.01 par value per share 2006-02-15 4 A 0 12500 A 39689 D Option to Purchase Common Stock, $.01 par value 4.62 2006-02-15 4 A 0 25000 0 A 2016-02-15 Common Stock, $.01 par value per share 25000 25000 D The right to receive these shares is pursuant to a restricted stock grant and such shares issue and vest as to 33.3% each on 02/15/07, 02/15/08 and 02/15/09, provided the grantee remains employed by the Company on these dates. These options will become exercisable as to 25% on each 2/15/07, 2/15/08, 2/15/09 and 2/15/10, provided the optionee remains employed by the Company on these dates. By: Beata A. Smith as Attorney-In-Fact for 2006-02-22 -----END PRIVACY-ENHANCED MESSAGE-----